
## Laura McCullagh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1601552/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Policies for biosimilar uptake in Europe: An overview. PLoS ONE, 2017, 12, e0190147.	1.1	153
2	Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. Expert Review of Clinical Pharmacology, 2015, 8, 77-94.	1.3	108
3	Personalizing health care: feasibility and future implications. BMC Medicine, 2013, 11, 179.	2.3	81
4	Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in Pharmacology, 2013, 4, 39.	1.6	75
5	A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting. Pharmacoeconomics, 2009, 27, 829-846.	1.7	60
6	Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. Frontiers in Pharmacology, 2016, 7, 305.	1.6	48
7	Evaluation of the General Practice Pharmacist (GPP) intervention to optimise prescribing in Irish primary care: a non-randomised pilot study. BMJ Open, 2020, 10, e035087.	0.8	33
8	General practitioners' views on malnutrition management and oral nutritional supplementation prescription in the community: A qualitative study. Clinical Nutrition ESPEN, 2020, 36, 116-127.	0.5	29
9	Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals*. HIV Medicine, 2006, 7, 248-254.	1.0	25
10	The Pharmacoeconomic Evaluation Process in Ireland. Pharmacoeconomics, 2016, 34, 1267-1276.	1.7	23
11	Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review. Value in Health, 2020, 23, 52-60.	0.1	23
12	Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland. Pharmacoeconomics, 2016, 34, 925-937.	1.7	20
13	An investigation of community-dwelling older adults' opinions about their nutritional needs and risk of malnutrition; a scoping review. Clinical Nutrition, 2021, 40, 2936-2945.	2.3	16
14	Healthcare professionals' perceptions of malnutrition management and oral nutritional supplement prescribing in the community: A qualitative study. Clinical Nutrition ESPEN, 2021, 44, 415-423.	0.5	13
15	Value-of-Information Analysis to Reduce Decision Uncertainty Associated with the Choice of Thromboprophylaxis after Total Hip Replacement in the Irish Healthcare Setting. Pharmacoeconomics, 2012, 30, 941-959.	1.7	11
16	The cost of the inpatient management of febrile neutropenia in cancer patients - a micro-costing study in the Irish healthcare setting. European Journal of Cancer Care, 2015, 24, 125-132.	0.7	10
17	Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group. Value in Health, 2020, 23, 1423-1426.	0.1	10
18	Malnutrition: A Misunderstood Diagnosis by Primary Care Health Care Professionals and Community-Dwelling Older Adults in Ireland. Journal of the Academy of Nutrition and Dietetics, 2021, 121, 2443-2453.	0.4	10

LAURA MCCULLAGH

#	Article	IF	CITATIONS
19	Transferability of Economic Evaluations of Treatments for Advanced Melanoma. Pharmacoeconomics, 2020, 38, 217-231.	1.7	9
20	Characteristics and determinants of high volume dispensing in long-term oral nutritional supplement users in primary care: a secondary analysis. BJGP Open, 2021, 5, BJGPO.2020.0131.	0.9	6
21	Neoadjuvant treatment for malignant and metastatic cutaneous melanoma. The Cochrane Library, 0, , .	1.5	4
22	A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland. European Journal of Health Economics, 2020, 21, 895-901.	1.4	4
23	Integrating clinical pharmacists within general practice: protocol for a pilot cluster randomised controlled trial. BMJ Open, 2021, 11, e041541.	0.8	4
24	Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis. International Journal of Technology Assessment in Health Care, 2022, 38, .	0.2	4
25	Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a) Tj ETQq1 Application to Drugs for Cancer. Pharmacoeconomics, 2017, 35, 1177-1185.	1 0.78431 1.7	4 rgBT /Over 3
26	Analysis of Health Technology Assessments of Orphan Drugs in Ireland from 2012 to 2017. PharmacoEconomics - Open, 2019, 3, 583-589.	0.9	3
27	The Interaction between Price Negotiations and Heterogeneity: Implications for Economic Evaluations. Medical Decision Making, 2020, 40, 144-155.	1.2	3
28	Disparities in Oral Nutritional Supplement Usage and Dispensing Patterns across Primary Care in Ireland: ONSPres Project. Nutrients, 2022, 14, 338.	1.7	3
29	The Utility of a Rapid Review Evaluation Process to a National HTA Agency. Pharmacoeconomics, 2022, 40, 203-214.	1.7	2
30	Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-Effective. Value in Health, 2021, 24, 1402-1406.	0.1	1
31	The Authors' Reply. Pharmacoeconomics, 2010, 28, 784-785.	1.7	0
32	VP82 Impact of Evidence Synthesis Methods on Outcome of Economic Evaluation. International Journal of Technology Assessment in Health Care, 2019, 35, 93-94.	0.2	0
33	A preliminary qualitative study of general practitioners' views on malnutrition management and oral nutritional supplementation prescription in the community. Proceedings of the Nutrition Society, 2020, 79, .	0.4	0
34	A preliminary qualitative study of nurses' and dietitians' views on malnutrition management and oral nutritional supplementation prescription in the community. Proceedings of the Nutrition Society, 2020, 79, .	0.4	0